Modified HpaB Oxidoreductase for L-DOPA Fermentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current production processes for L-DOPA, a precursor to dopamine used in treating Parkinson's disease, face inefficiencies in chemical synthesis and high raw material costs in enzymatic conversion, necessitating an economically attractive fermentative process with optimized tyrosine productivity and conversion to L-DOPA.
Innovation Solution
Mutations in the oxidoreductase HpaB enzyme, specifically amino acid exchanges at defined positions, enhance the production and conversion rate of L-DOPA, utilizing a polynucleotide encoding an amino acid sequence at least 50% identical to certain oxidoreductases, leading to increased enzyme activity and efficiency in microbial fermentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemical synthesis methods (asymmetric hydrogenation or hydrogenation and chiral resolution) are used for L-DOPA production, then the manufacturing process is well-established, but the conversion rate and overall efficiency are poor
Solution Approach 1:
The patent replaces chemical synthesis methods (mechanical/chemical system) with an enzymatic system using HpaB and HpaC enzymes. This substitution enables the fermentative production of L-DOPA from L-tyrosine, achieving higher conversion rates and enantioselectivity while maintaining ease of manufacture through established fermentation technologies.
Solution Approach 2:
The patent optimizes enzyme parameters including amino acid substitutions in HpaB (such as F289L, F289V, F289I, F289M, F289P, F289A, F289G, F289S, F289T, F289C, F289Y, F289H, F289R, F289K, F289Q, F289E, F289D, F289N, F289W, F289X, F289Z) to enhance catalytic activity and substrate specificity, thereby improving conversion rate while maintaining process feasibility.
2Productivity
If enzymatic conversion (enzymatic coupling of pyruvate and catechol) is used for L-DOPA production, then the conversion rate is improved, but the raw material cost is high
Solution Approach 1:
The patent changes the substrate parameter from expensive pyruvate/catechol to L-tyrosine, which is a more economical raw material. The HpaB enzyme catalyzes the hydroxylation of L-tyrosine to L-DOPA, achieving high conversion rates while reducing raw material costs through this parameter change in substrate selection.
Solution Approach 2:
The patent uses a genetically engineered microbial system that copies and expresses the HpaB and HpaC enzyme systems within host cells (such as E. coli or Pseudomonas putida). This allows the enzymatic conversion to occur in situ, eliminating the need for expensive external enzyme additions and reducing overall process costs while maintaining high conversion efficiency.
3Adaptability or versatility
If the HpaB enzyme activity with L-tyrosine is low (5% of activity with natural substrate 4-HPA), then the substrate spectrum is broad, but the enzyme activity for L-DOPA production is insufficient
Solution Approach 1:
The patent applies local quality modification by introducing specific amino acid substitutions at key positions in the HpaB enzyme active site (particularly around residue 289). These localized changes enhance the enzyme's catalytic activity toward L-tyrosine while preserving the overall substrate spectrum and structural integrity of the enzyme.
Solution Approach 2:
The patent changes the enzyme's kinetic parameters through rational design of amino acid substitutions. The modifications optimize substrate binding affinity and catalytic turnover rate for L-tyrosine, transforming the enzyme from having low activity (5%) with this substrate to high activity, thereby resolving the contradiction between versatility and productivity.
4Productivity
If tyrosine productivity is optimized and conversion of L-tyrosine to L-DOPA is increased, then the economic attractiveness improves, but the process complexity increases
Solution Approach 1:
The patent merges the L-tyrosine production pathway and the L-DOPA conversion pathway into a single integrated fermentative process. By co-expressing HpaB (tyrosine hydroxylase) and HpaC (reductase) in the same microbial host, the system achieves both high tyrosine productivity and efficient conversion to L-DOPA in one bioreactor, simplifying overall process complexity while enhancing productivity.
Solution Approach 2:
The engineered microbial system performs self-service by autonomously carrying out both L-tyrosine synthesis and its conversion to L-DOPA through the expressed HpaB and HpaC enzymes. The cells utilize available carbon sources to produce L-tyrosine and simultaneously convert it to L-DOPA, eliminating the need for separate process steps and reducing operational complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified HpaB enzyme significantly increases L-DOPA production and conversion rates, achieving higher end concentrations and scalability, thereby improving the economic viability and efficiency of the fermentative process for L-DOPA production.
Implementation Method 1
the 4-hydroxyphenylacetate 3-monooxygenase HpaB and the cognate 4-hydroxyphenylacetate 3-monooxygenase reductase HpaC from Escherichia coli (E. coli)
Implementation Method 2
Polynucleotide encoding an amino acid sequence, encoding an oxidoreductase
Data Source
AI summary
A polynucleotide, encoding an amino acid sequence, encoding an oxidoreductase, that is ≥50% identical to an amino acid sequence of SEQ ID NO:1 (Geobacillus sp. PA9), SEQ ID NO:3 (Thermus thermophilus), SEQ ID NO:4 (Streptomyces globisporus), SEQ ID NO:5 (Clostridium aminobutyricum), SEQ ID:6 (Burkholderai cepacia), SEQ ID NO:8 (Oscillatoria sp. PCC 6506), or SEQ ID NO:9 (Paraburkholderia phymatum). The polynucleotide has an amino acid exchange in one or more of positions 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214 of SEQ ID NO:1, or at a corresponding position of the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID:5, SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:9.